

Phonetic Orthographic Computer Analysis (POCA) System

Presented by R. F. Shangraw, Jr., Ph.D. Project Performance Corporation

Presented to 40th Annual Conference of the Drug Information Association Washington, D.C.
June 16, 2004

Outline

- Overall System Design
- The Medical Repository
- Algorithm Testing
- System Demonstration



System Objectives

- Accessibility
 - Web-based
 - Varying levels of permission for varied tasks
 - Ease of use
- Efficient Use of Expert Time
 - Decrease paper production
 - Increase analysis time while decreasing search time
- Scientifically-Based Analysis
 - Reliability of Algorithms
 - Predictive Validity of Algorithms




System History

- Pilot System Development Funded by the U.S. Food and Drug Administration (FDA)
- Development Team
 - Project Performance Corporation
 - Bonnie Dorr, University of Maryland
 - Greg Kondrak, University of Alberta
- Pilot System Under Evaluation by FDA




Safety Evaluation Process – Before

Before Computer Analysis:






POCA System Architecture



Safety Evaluation Process – Computer Assisted

With Computer Analysis:





Medical Repository

- Oracle Database
- Features
 - Populated with FDA Corporate Database
 - Approved and Unapproved Proprietary Names
 - Ability to Include Additional Factors Such As Drug Strengths, Dosing Intervals, Dosage Forms and Routes of Administration. Feature Not Yet Implemented.
 - Ability to Manually Update the Repository
 - Ability to Import Data with Database Tools
- Next Steps
 - Biologics
 - Supplements and Herbals
 - Medical Terminology



How do you Measure Success?

Recall and Precision

- Recall The percentage of relevant names retrieved by the search
- Precision The percentage of retrieved names relevant to the search

Recall –
$$A \cap B$$

A


Precision – $A \cap B$
 B

A = Gold Standard

B = Retrieved Names



Phonetic Algorithm Validation Results



10

Pilot System Performance


- FDA Requirement: Empirical comparisons of the system's ability to identify at least 75% of the potentially confusing names that have been identified by all the FDA safety evaluators during the 100 most recently completed reviews.
- Project Outcome: The pilot system identified 92.5% of the names identified by the FDA safety evaluators during the 100 most recently completed reviews.





File Edit View Favorites Tools Help







Disclaimer


This is a Federal computer system and is the property of the United States Government. It is for authorized use only. Users (authorized or unauthorized) have no explicit or implicit expectation of privacy.

Any or all use of this system and all files on this system may be intercepted, monitored, recorded, copied, audited, inspected, and disclosed to authorized site, Food and Drug Administration, and law enforcement personnel, as well as authorized officials of other agencies, both domestic and foreign. By using this system, the user consents to such interception, monitoring, recording, copying, auditing, inspection, and disclosure at the discretion of authorized site or Food and Drug Administration personnel.

Unauthorized or improper use of this system may result in administrative disciplinary action and civil and criminal penalties. By continuing to use this system you indicate your awareness of and consent to these terms and conditions of use. LOG OUT IMMEDIATELY if you do not agree to the conditions stated in this warning.









<u>File Edit View Favorites Tools Help</u>

Welcome Jessica Toye. Today is 6/14/2004

Home | Search | Settings | Comments | Help | Logout



New Search

Search Results

Search Term: Claritin

Add to Watch List

Orthographic & Phonetic Matches greater then 65%

	Name of Concern	Match Percentage ▼
	CLARITIN	100
	CLARITIN-D	87
		74
	THE PERSON NAMED IN COLUMN 1	72
		71
		70
9	244424	68
		68
	of All Control	68
	100	68
		67
	ESURINGIA	66
		66

Product Details For CLARITIN - Microsoft Internet Explorer

Product Details for CLARITIN

Dosage Form:

Drug Strength: 1MG/1ML
Route of Administration: ORAL
Active Ingredient: LORATADINE
Drug Strength: 10MG
Dosage Form: TABLET

Phonetic Matches greater then 65%

@ Done

Name of Concern	Match Percentage	
	- 	
CLARITIN	100	

